Investments
41Portfolio Exits
17About JAFCO Life Science Investment
JAFCO Life Science Investment, part of Tokyo-based publicly-traded venture capital firm JAFCO, aims to invest in U.S.-based later-stage biopharmaceutical and medical device companies and create value for portfolio companies by facilitating partnerships with Japanese companies. JAFCO has extensive networks with pharmaceutical and medical device companies in Japan and holds a JAFCO Biotechnology Conference in November of every year in Tokyo.
JAFCO Life Science Investment Headquarter Location
Tokyo,
Japan
Latest JAFCO Life Science Investment News
Apr 20, 2011
XconomySan Diego — San Diego’s Tracon Pharmaceuticals says today it has raised $14 million of a planned $22 million round of venture capital needed to advance development of TRC105, a promising therapeutic that inhibits the growth of new blood vessels that supply tumors. The National Cancer Institute also is supporting the company’s research and development, which includes ongoing trials in prostate, bladder, and liver cancer. JAFCO, the Tokyo-based, publicly traded venture capital group, and Nextech Invest, a specialized oncology fund based in Zurich, Switzerland, led the investment round. They were joined by New York-based Arcus Ventures and the Tokyo-based venture firm BHP. Existing investor Brookline Investments of Birmingham, AL, also participated. In a statement from the company , Tracon CEO Charles Theuer says the funding will enable the company to build on promising early stage research and complete multiple mid-stage trials of the antibody TRC105. Tracon says it is testing the antibody on a new tumor vascular target known as CD-105, as both a monotherapy and in combination with existing vascular endothelial growth factor (VEGF) inhibitors as well as chemotherapy. JAFCO’s Kenji Harada and Hironori Hozoji (a San Diego-based investment officer with JAFCO Life Science Investment) are joining Tracon’s board, along with Nextech managing partner Myoung-Ok Kwon. Tracon says two prominent oncologists, Harvard University’s William G. Kaelin and Charles L. Sawyers of the Memorial Sloan-Kettering Cancer Center also were named to the company’s scientific advisory board.
JAFCO Life Science Investment Investments
41 Investments
JAFCO Life Science Investment has made 41 investments. Their latest investment was in Complexa as part of their Series C - II on April 4, 2019.
JAFCO Life Science Investment Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
4/16/2019 | Series C - II | Complexa | $11M | No | 2 | |
9/28/2017 | Series B | Magenta Medical | $15M | Yes | 5 | |
7/26/2017 | Series C | Complexa | $62M | No | 4 | |
6/4/2014 | Series B | |||||
12/2/2013 | Series B |
Date | 4/16/2019 | 9/28/2017 | 7/26/2017 | 6/4/2014 | 12/2/2013 |
---|---|---|---|---|---|
Round | Series C - II | Series B | Series C | Series B | Series B |
Company | Complexa | Magenta Medical | Complexa | ||
Amount | $11M | $15M | $62M | ||
New? | No | Yes | No | ||
Co-Investors | |||||
Sources | 2 | 5 | 4 |
JAFCO Life Science Investment Portfolio Exits
17 Portfolio Exits
JAFCO Life Science Investment has 17 portfolio exits. Their latest portfolio exit was Sesen Bio on February 06, 2014.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
2/6/2014 | IPO | Public | 2 | ||
10/11/2012 | IPO | Public | 1 | ||
10/11/2012 | IPO | Public | |||
Date | 2/6/2014 | 10/11/2012 | 10/11/2012 | ||
---|---|---|---|---|---|
Exit | IPO | IPO | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | Public | Public | ||
Sources | 2 | 1 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.